Publications by authors named "Gregory Moeck"

Claim this Profile
M
Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases.
Cassandra L Chatwin, Jodie C Hamrick, Robert E L Trout, Cullen L Myers, Susan M Cusick, Gregory Moeck

Antimicrob Agents Chemother· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci.
Francis F Arhin, David Lalonde Seguin, Adam Belley, Gregory Moeck

Diagn Microbiol Infect Dis· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the potential for oritavancin MIC changes among Staphylococcus aureus nasal carriage isolates following systemic oritavancin treatment in a phase 2 study in patients with acute bacterial skin and skin-structure infections.
Francis F Arhin, Gregory Moeck

J Glob Antimicrob Resist· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Agar dilution minimum inhibitory concentrations under-represent oritavancin in vitro activity against staphylococci and enterococci.
Francis F Arhin, Gregory Moeck

J Glob Antimicrob Resist· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015.
James A Karlowsky, Andrew J Walkty, Melanie R Baxter, Francis F Arhin, Gregory Moeck

Diagn Microbiol Infect Dis· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
Douglas J Biedenbach, Francis F Arhin, Gregory Moeck, Thomas F Lynch, Daniel F Sahm

Int J Antimicrob Agents· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene.
Francis F Arhin, Ingrid Sarmiento, Gregory Moeck

Int J Antimicrob Agents· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA).
Francis F Arhin, Ingrid Sarmiento, Gregory Moeck

Int J Antimicrob Agents· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between oritavancin and vancomycin minimum inhibitory concentrations in staphylococci.
Francis F Arhin, Deborah C Draghi, Chris M Pillar, Gregory Moeck, Daniel F Sahm

Int J Antimicrob Agents· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model.
Jane Freeman, Miriam Marquis, Grace S Crowther, Sharie L Todhunter, Warren N Fawley, Gregory Moeck

J Antimicrob Chemother· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus.
Francis F Arhin, Ingrid Sarmiento, Thomas R Parr, Gregory Moeck

Int J Antimicrob Agents· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
Adam Belley, Geoffrey A McKay, Francis F Arhin, Ingrid Sarmiento, Sylvain Beaulieu, Gregory Moeck

Antimicrob Agents Chemother· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008.
Francis F Arhin, Gregory Moeck, Deborah C Draghi, Chris M Pillar, Daniel F Sahm

Int J Antimicrob Agents· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of oritavancin serum protein binding across species.
Francis F Arhin, Adam Belley, Geoffrey McKay, Sylvain Beaulieu, Ingrid Sarmiento, Gregory Moeck

Antimicrob Agents Chemother· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis.
Kelly S E Tanaka, Evelyne Dietrich, Stéphane Ciblat, Claude Métayer, Francis F Arhin, Gregory Moeck

Bioorg Med Chem Lett· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the in vitro activity of novel lipoglycopeptide antibiotics.
Francis F Arhin, Adam Belley, Geoffrey A McKay, Gregory Moeck

Curr Protoc Microbiol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative in vitro activity of oritavancin against recent, genetically diverse, community-associated meticillin-resistant Staphylococcus aureus (MRSA) isolates.
Francis F Arhin, Natalia Kurepina, Ingrid Sarmiento, Thomas R Parr, Gregory Moeck

Int J Antimicrob Agents· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital.
Pierre Vaudaux, Elzbieta Huggler, Francis F Arhin, Gregory Moeck, Adriana Renzoni

Int J Antimicrob Agents· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes.
Francis F Arhin, Geoffrey A McKay, Sylvain Beaulieu, Ingrid Sarmiento, Thomas R Parr, Gregory Moeck

Int J Antimicrob Agents· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
Francis F Arhin, Deborah C Draghi, Chris M Pillar, Thomas R Parr, Gregory Moeck

Antimicrob Agents Chemother· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin.
Francis F Arhin, Ingrid Sarmiento, Thomas R Parr, Gregory Moeck

J Antimicrob Chemother· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus.
Francis F Arhin, Geoffrey A McKay, Sylvain Beaulieu, Ingrid Sarmiento, Thomas R Parr, Gregory Moeck

Diagn Microbiol Infect Dis· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of human serum albumin on oritavancin in vitro activity against enterococci.
Geoffrey A McKay, Sylvain Beaulieu, Ingrid Sarmiento, Francis F Arhin, Thomas R Parr, Gregory Moeck

Antimicrob Agents Chemother· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
Geoffrey A McKay, Sylvain Beaulieu, Francis F Arhin, Adam Belley, Ingrid Sarmiento, Gregory Moeck

J Antimicrob Chemother· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of transcription in Staphylococcus aureus by a primary sigma factor-binding polypeptide from phage G1.
Mohammed Dehbi, Gregory Moeck, Francis F Arhin, Pascale Bauda, Dominique Bergeron

J Bacteriol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis